Article Text

Download PDFPDF
Dexmedetomidine withdrawal syndrome and opioid sensitivity
  1. Lana Ferguson and
  2. Stacey Hooper
  1. Palliative Care, Waikato District Health Board, Hamilton, New Zealand
  1. Correspondence to Dr Lana Ferguson, Palliative Care, Waikato District Health Board, Hamilton 3204, New Zealand; lana.ferguson2{at}


This case report describes the use of dexmedetomidine for refractory cancer pain management in a patient with significant pelvic disease due to metastatic urothelial cancer. Specifically, the management of increased opioid sensitivity secondary to dexmedetomidine is discussed. Further, the phenomenon of dexmedetomidine withdrawal syndrome and our management of this is addressed.

  • cancer
  • pain
  • drug administration

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Correction notice This article has been corrected since it first published. The provenance and peer review statement has been included.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.